Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
A post-loading method combined mRNA with preformed empty lipid nanoparticles using heat and acidic conditions, achieving roughly 90% encapsulation. The particles produced protein expression in mouse liver and spleen, although activity was slightly below conventional microfluidic formulations. Greater payload heterogeneity emerged as a potential limitation; the method supports 96-well preparation.
Medicilon reported consolidated revenue of RMB1.215 billion, up 44.13%, and attributable net income of RMB92.0 million for the nine months ended September 30, 2026. The company returned to profit. Its report does not present a conventional positive-base growth rate for attributable earnings. The quarterly filing is unaudited and covers the year-to-date period.
Based on the article abstract, a review of 20 approved small-molecule medicines for selected chronic inflammatory diseases found more than 25% higher exposure in patients for five medicines, using reported population pharmacokinetic analyses. The authors highlight CYP3A4 and CYP2C19 metabolism. This cross-drug review supports risk assessment, not automatic dose changes for individual patients.
Lonza announced three planned multiproduct bioconjugation suites in Visp, with operations expected from 2028, alongside 500-liter single-use upgrades scheduled for 2027. A November 2 update revised the new facility's maximum scale from 1,200 to 3,000 liters. The capacity remains under development; the announcement does not establish available current commercial slots.
Based on the PubMed abstract, researchers combined guanidine-bridged nucleic acid and MOE modifications in antisense gapmers, reporting improved knockdown in laboratory and animal experiments. Activity persisted beyond 24 weeks in mouse brain after intracerebroventricular administration. The study also examined immune responses and toxicity; these preclinical results do not establish human safety or efficacy.
JOINN Laboratories reported consolidated revenue of RMB1.188 billion, up 20.60%, and attributable net income of RMB929.7 million for the nine months ended September 30, 2026. Biological-asset fair-value changes contributed approximately RMB866.3 million in net gains, materially affecting reported earnings. The quarterly filing is unaudited and covers the year-to-date period.
Codis has moved its Haverhill expansion into construction after completing demolition of redundant facilities. The project will add a solvent-capable GEA PSD-4 spray dryer for commercial-scale amorphous solid dispersions and connect with formulation, analytical, clinical supply, and oral solid dose services in Nottingham. Additional capacity is expected in the fourth quarter of 2027, after installation and validation.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Researchers produced spherical cyclandelate and cyclandelate–tenoxicam particles in water using thermally induced liquid–liquid phase separation. Stirring controlled droplet and particle-size distributions. Under selected conditions, angles of repose fell by roughly 43%–46% versus raw materials. The study combines particle measurements with molecular simulations; it does not establish improved clinical performance or commercial-scale manufacturability.
An npj Drug Discovery review examines how generative models represent constrained peptide chemistry, topology, conformational ensembles, and developability. It separates information explicitly generated by a model from properties inferred later, and predictions from prospective experiments. The authors identify gaps in chemical coverage and uncertainty calibration, including limitations relevant to orally absorbed cyclic peptides.
Processa announced a research collaboration and exclusive option agreement with Generian Pharmaceuticals to advance an oral macrocyclic peptide FcRn antagonist program. The companies aim to develop oral alternatives to injectable treatments for IgG-mediated autoimmune diseases. The announcement disclosed neither human data for the peptide program nor financial terms; a separate BTK program received Phase 2 IND clearance.
HitGen reported consolidated revenue of RMB0.550 billion, up 48.73%, and attributable net income of RMB139.4 million for the nine months ended September 30, 2026. Attributable net income increased 50.11%. These are consolidated year-to-date figures rather than third-quarter-only results. The quarterly filing is unaudited and covers the year-to-date period.
